TNGX
Live chart
What they do
Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
For information only · Important disclosures
Grades vs sector
No sector grades for TNGX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.
Systematic Models
Not held by any of our 5 live models right now.
News
More newsKey stats
Valuation and fundamentals
Valuation & fundamentals
Earnings
| Report | EPS est | Actual | Surprise |
|---|---|---|---|
| 2026-08-11 | -0.32 | -0.37 | -14.2% |
| 2026-05-13 | -0.31 | -0.32 | -1.7% |
| 2026-03-05 | -0.33 | -0.29 | +11.8% |
| 2025-11-04 | -0.07 | 0.13 | +287.4% |
| 2025-08-05 | -0.34 | -0.35 | -1.9% |
| 2025-05-12 | -0.35 | -0.36 | -4.1% |
| 2025-02-27 | -0.34 | -0.34 | +0.8% |
| 2024-11-06 | -0.37 | -0.27 | +27.9% |
Quarterly revenue
| Quarter | Revenue | YoY |
|---|---|---|
| 2026-06-30 | $0 | -100.0% |
| 2026-03-31 | $0 | – |
| 2025-12-31 | $0 | – |
| 2025-09-30 | $53.8M | – |
| 2025-06-30 | $3.2M | – |
Rating changes
Third-party analyst actions, not Coteau's views. All rating changes
Insider trades
$15.2K
$645.6K
$60.4K
$122.2K
$16.0K
$603.9K
$594.4K
$141.1K
Stats refreshed 2026-10-21 12:15:37 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now
Free to use. No card, no ads, no auto-renew.
Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app
Beta 0.9 · Oct 21, 2026